ENTA ENANTA PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ENANTA PHARMACEUTICALS INC reported revenue of $14.4M (down 21.6% from a year earlier), net income of −$19.5M and diluted EPS of −$0.67; over the last four quarters revenue was $65.3M and net income −$63.2M; for the fiscal year ended September 2025 revenue was $65.3M, down 3.4% on the year before.

ENTA annual revenue and earnings

• Fiscal year ended Sep 2025: revenue $65.3M, gross profit n/a, operating income −$85.3M, net income −$81.9M (margin -125.4%), EPS −$3.84
• Fiscal year ended Sep 2024: revenue $67.6M, gross profit n/a, operating income −$122M, net income −$116M (margin -171.6%), EPS −$5.48
• Fiscal year ended Sep 2023: revenue $79.2M, gross profit n/a, operating income −$137M, net income −$134M (margin -169.0%), EPS −$6.38
• Fiscal year ended Sep 2022: revenue $86.2M, gross profit n/a, operating income −$124M, net income −$122M (margin -141.3%), EPS −$5.91
• Fiscal year ended Sep 2021: revenue $97.1M, gross profit n/a, operating income −$110M, net income −$79.0M (margin -81.4%), EPS −$3.92

ENTA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $14.4M (down 21.6% year over year), net income −$19.5M, EPS −$0.67
• Quarter ended Mar 31, 2026: revenue $17.2M (up 15.0% year over year), net income −$13.1M, EPS −$0.45
• Quarter ended Dec 31, 2025: revenue $18.6M (up 9.8% year over year), net income −$11.9M, EPS −$0.42
• Quarter ended Sep 30, 2025 (from the annual report): revenue $15.1M (up 3.5% year over year), net income −$18.7M, EPS −$0.88
• Quarter ended Jun 30, 2025: revenue $18.3M (up 1.9% year over year), net income −$18.3M, EPS −$0.85
• Quarter ended Mar 31, 2025: revenue $14.9M (down 12.5% year over year), net income −$22.6M, EPS −$1.06
• Quarter ended Dec 31, 2024: revenue $17.0M (down 5.8% year over year), net income −$22.3M, EPS −$1.05
• Quarter ended Sep 30, 2024 (from the annual report): revenue $14.6M (down 22.8% year over year), net income −$28.8M, EPS −$1.36
• Quarter ended Jun 30, 2024: revenue $18.0M (down 4.9% year over year), net income −$22.7M, EPS −$1.07
• Quarter ended Mar 31, 2024: revenue $17.1M (down 4.2% year over year), net income −$31.2M, EPS −$1.47
• Quarter ended Dec 31, 2023: revenue $18.0M (down 23.7% year over year), net income −$33.4M, EPS −$1.58
• Quarter ended Sep 30, 2023 (from the annual report): revenue $18.9M (down 6.8% year over year), net income −$28.1M, EPS −$1.34
• Quarter ended Jun 30, 2023: revenue $18.9M (down 3.0% year over year), net income −$39.1M, EPS −$1.86
• Quarter ended Mar 31, 2023: revenue $17.8M (down 4.9% year over year), net income −$37.7M, EPS −$1.79
• Quarter ended Dec 31, 2022: revenue $23.6M (down 14.7% year over year), net income −$29.0M, EPS −$1.39
• Quarter ended Sep 30, 2022 (from the annual report): revenue $20.3M, net income −$26.3M, EPS −$1.27
• Quarter ended Jun 30, 2022: revenue $19.5M (down 9.9% year over year), net income −$31.7M, EPS −$1.53
• Quarter ended Mar 31, 2022: revenue $18.7M (down 7.0% year over year), net income −$33.6M, EPS −$1.63
• Quarter ended Dec 31, 2021: revenue $27.6M, net income −$30.1M, EPS −$1.48
• Quarter ended Jun 30, 2021: revenue $21.6M, net income −$24.0M, EPS −$1.19

ENTA cash flow, buybacks and dividends

• Fiscal year ended Sep 2025: operating cash flow −$19.3M, share buybacks n/a
• Fiscal year ended Sep 2024: operating cash flow −$78.8M, share buybacks n/a
• Fiscal year ended Sep 2023: operating cash flow −$103M, share buybacks n/a
• Fiscal year ended Sep 2022: operating cash flow −$84.8M, share buybacks n/a
• Fiscal year ended Sep 2021: operating cash flow −$70.0M, share buybacks n/a

ENTA balance sheet

• Jun 30, 2026: cash $33.4M, total assets $297M, total liabilities $196M, shareholders' equity $101M
• Mar 31, 2026: cash $34.9M, total assets $315M, total liabilities $198M, shareholders' equity $117M
• Dec 31, 2025: cash $37.4M, total assets $330M, total liabilities $203M, shareholders' equity $127M
• Sep 30, 2025: cash $32.3M, total assets $281M, total liabilities $216M, shareholders' equity $64.7M
• Jun 30, 2025: cash $44.8M, total assets $301M, total liabilities $222M, shareholders' equity $79.3M
• Mar 31, 2025: cash $60.2M, total assets $323M, total liabilities $229M, shareholders' equity $93.5M
• Dec 31, 2024: cash $84.3M, total assets $349M, total liabilities $237M, shareholders' equity $112M
• Sep 30, 2024: cash $37.2M, total assets $377M, total liabilities $248M, shareholders' equity $129M

What is ENTA's revenue?

ENANTA PHARMACEUTICALS INC reported $65.3M of revenue over its last four quarters, through June 30, 2026.

Is ENTA profitable?

No. ENANTA PHARMACEUTICALS INC lost $63.2M over the last four quarters.

What is ENTA's EPS?

Diluted earnings per share over the last four quarters were −$2.42; −$0.67 in the latest quarter.

ENTA ownership and insider trades · All stocks